Key points from article :
A recent study utilizing Whole Body Digital Twin technology powered by artificial intelligence (AI) has demonstrated one of the highest remission rates for type 2 diabetes to date. The findings were presented at the 82nd Scientific Sessions of the American Diabetes Association in New Orleans. The study aimed to compare the effectiveness of Twin Precision Treatment (TPT) technology with standard care (SC) in achieving type 2 diabetes remission and improving metabolic health.
Researchers conducted a randomized controlled trial involving 319 patients with an average age of 45 and a diabetes duration of nearly four years. The TPT intervention, which uses AI and the Internet of Things (IoT), provided personalized guidance for nutrition, sleep, activity, and breathing through a mobile app. Patients were monitored at 90-day intervals to track changes in their A1C levels and overall diabetes management.
After 180 days, interim analysis showed that 94.9% of TPT patients achieved an A1C level of less than 6.5% without medication or only with metformin. Moreover, 83.9% of TPT patients met the American Diabetes Association’s criteria for diabetes remission, compared to those under standard care. Notably, all insulin-dependent patients in the TPT group stopped using insulin within the first 90 days.
Whole Body Digital Twin technology could shift diabetes management away from a medication-driven approach toward achieving remission through personalized care. The technology is built on thousands of daily data points from non-invasive sensors, offering a tailored model of each patient's metabolism.
While the results are promising, the researchers note that long-term studies are required to confirm the durability of the remission and the broader impact of this AI-based intervention on global populations suffering from metabolic diseases.
